WO2001045668A2 - Composition de dose orale a liberation prolongee - Google Patents

Composition de dose orale a liberation prolongee Download PDF

Info

Publication number
WO2001045668A2
WO2001045668A2 PCT/US2000/034412 US0034412W WO0145668A2 WO 2001045668 A2 WO2001045668 A2 WO 2001045668A2 US 0034412 W US0034412 W US 0034412W WO 0145668 A2 WO0145668 A2 WO 0145668A2
Authority
WO
WIPO (PCT)
Prior art keywords
film
desloratadine
hours
oral dosage
extended release
Prior art date
Application number
PCT/US2000/034412
Other languages
English (en)
Other versions
WO2001045668A3 (fr
Inventor
Jim H. Kou
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22629437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001045668(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AU22771/01A priority Critical patent/AU2277101A/en
Publication of WO2001045668A2 publication Critical patent/WO2001045668A2/fr
Publication of WO2001045668A3 publication Critical patent/WO2001045668A3/fr
Priority to US10/175,460 priority patent/US6979463B2/en
Priority to US11/244,743 priority patent/US7820199B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to a film-coated extended release solid oral dosage composition containing a nasal decongestant, e.g., pseudoephedrine in a controlled release core and a film outer coating containing the non-sedating antihistamine, desloratadine.
  • the solid oral dosage compositions of this invention are useful for treating patients showing the signs and symptoms associated with allergic and/or inflammatory conditions such as the common cold, as well as signs and symptoms associated with allergic and/or inflammatory conditions of the skin or upper and lower airway passages such as allergic rhinitis, seasonal allergic rhinitis and nasal congestion, upper respiratory diseases, allergic rhinitis and nasal congestion.
  • Desloratadine also called descarbethoxyloratadine
  • US Patent No. 4,659,716 as a non-sedating antihistamine useful as an anti-allergy agent .
  • US Patent No. 6,100,274 discloses compositions containing desloratadine.
  • US Patent No. 5,595,997 discloses methods and compositions for treating seasonal allergic rhinitis symptoms using desloratadine.
  • Desloratadine upon oral absorption, is hydroxylated at the 3 position to produce the metabolite, 3-hydroxyldesloratadine.
  • U. S. Patent Nos. 4,990,535 and 5,100,675 disclose a twice-a-day sustained release coated tablet wherein the tablet coating comprises descarbethoxyloratadine and a hydrophilic polymer and polyethylene glycol, and the tablet core comprises acetaminophen, pseudoephedrine or a salt thereof, a swellable hydrophilic polymer and pharmaceutically acceptable excipients.
  • U. S. Patent No. 5,314,697 discloses an extended release tablet
  • matrix core comprising pseudoephedrine sulfate and a coating comprising loratadine.
  • the present invention provides film-coated extended release solid oral dosage composition
  • a core comprising an effective amount of pseudoephedrine or pharmaceutically acceptable salt thereof
  • a film coating uniformly covering the core and comprising an effective amount of desloratadine wherein the amount of pseudoephedrine or pharmaceutically acceptable salt thereof is effective to produce a geometric maximum plasma concentration of pseudoephedrine of about 345 ng/mL to about 365 ng/mL at a time of about 7.60 hrs to about 8.40 hrs and the amount of desloratadine is effective to produce a geometric maximum plasma concentration of desloratadine of about 2.10 ng/mL to about 2.45 ng/mL at a time of about 4.0 hours to about 4.5 hours after administration of a single dose of said composition.
  • Preferred embodiments of the film-coated extended release solid oral dosage composition of the present invention also produce a geometric maximum plasma concentration of 3-hydroxydesloratadine of about 0.75 ng/mL to about 1.15 ng/mL at a time of about 5.50 hours to about 6.25 hours after administration of a single dose of said composition.
  • More preferred embodiments of the film-coated extended release solid oral dosage composition of the present invention also produce a geometric maximum plasma concentration of desloratadine of about 2.10 ng/mL to about 2.45 ng/mL at a time of about 4.0 hours to about 4.5 hours and a geometric maximum plasma concentration of 3- hydroxydesloratadine of about 0.75 ng/mL to about 1.15 ng/mL at a time of about 5.50 hours to about 6.25 hours after administration of a single dose of said composition.
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising therapeutically effective amount of pseudoephedrine sulfate in a core and an effective amount of desloratadine in a film coating maintaining the desirable pharmacokinetic parameters of desloratadine, 3-hydroxydesloratadine and pseudoephedrine listed herein above and containing less than about 2 % of desloratadine decomposition products such as N-formyldesloratadine, preferably less than about 1.4% to about 1.6 % of the desloratadine decomposition products such as N-formyldesloratadine, initially, as well as when such compositions are stored at 25°C and about 60% relative humidity for periods of at least about 24 months.
  • a nasal decongestant e.g., pseudoephedrine salt, preferably pseudoephedrine sulfate
  • a nasal decongestant e.g., pseudoephedrine salt, preferably pseudoephedrine sulfate
  • the core preferably a matrix core
  • the present invention provides a film-coated extended release solid oral dosage composition comprising:
  • a second film coating uniformly covering the first coating comprising: 1. an immediate release amount of desloratadine;
  • This preferred embodiment of the film-coated extended release solid oral dosage composition of the present invention releases at least about 80% of the desloratadine into a 0.1 N HCI solution at 37°C within about 45 minutes and about 64% of the pseudoephedrine sulfate in 6 hours and 88% of the pseudoephedrine sulfate in 12 hours in a USP
  • the film-coated extended release oral dosage composition contains less than about 2% of the the desloratadine decomposition products such as N-formyldesloratadine.
  • the present invention provides a film- coated extended release solid oral dosage composition comprising:
  • Pseudoephedrine Sulfate about 240
  • a lubricant selected from talc, silicon dioxide and magnesium stearate
  • a lubricant selected from talc, silicon dioxide and magnesium stearate
  • polyethylene glycol selected from polyethylene glycol 200 to polyethylene glycol 8000; and optionally
  • the above-listed preferred film-coated extended solid oral dosage composition may further comprise a third film coating uniformly covering the second film coating, wherein the third film coating comprises:
  • a lubricant selected from talc, silicon dioxide and magnesium stearate
  • a water-soluble film-modifying agent selected from low viscosity hydroxypropyl cellulose, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose, and a polyethylene glycol selected from polyethylene glycol 200 to polyethylene glycol 8000 or mixtures thereof;
  • the present invention provides a film-coated extended release solid oral dosage composition comprising:
  • Pseudoephedrine Sulfate about 240
  • magnesium stearate about 1.36-about 4.08
  • glycol 6000 to a polyethylene glycol 8000
  • a lubricant selected from talc, silicon dioxide and
  • magnesium stearate about 3.5-about 10.5
  • a polyethylene glycol selected from a polyethylene glycol 6000 to a polyethylene glycol 8000; about 0.915-about 2.75
  • silica gel about 0.14-about 042
  • the present invention provides a film-coated extended release oral dosage composition
  • a film-coated extended release oral dosage composition comprising: a. a matrix core comprising:
  • Pseudoephedrine Sulfate about 240
  • Silicon Dioxide and about 6-12
  • a lubricant selected from talc, silicon dioxide and magnesium stearate
  • a polyethylene glycol selected from a polyethylene glycol 200 to polyethylene glycol 8000; and (4) optionally a pharmaceutically acceptable mixture of homologous liquid methyl siloxane polymers and silica gel;
  • a second film coating uniformly covering the first coating comprising: (1 ) an amount of desloratadine effective to produce a geometric maximum plasma concentration of desloratadine of about 2.10 ng/mL to about 2.45 ng/mL at a time of about 4.0 hours to about 4.5 hours after administration of a single dose of said composition;
  • a lubricant selected from talc, silicon dioxide and magnesium stearate
  • a polyethylene glycol selected from a polyethylene glycol 200 to a-polyethylene 8000; and (5) optionally a pharmaceutically acceptable mixture of homogous liquid methyl siloxane and polymers and silica gel.
  • composition of the present invention is provided herein below: 1. Matrix Core Ingredient mg/core
  • Matrix Core Weight 800mg 1. Matrix Core Coatings
  • Matrix Core Weight 800mg 2.
  • Matrix Core Coatings 1. First Film Coating: Ingredient mg/tablet
  • pseudoephedrine salt e.g., pseudo-ephedhne hydrogen chloride
  • compositions of the present invention are useful for treatment of allergic and/or inflammatory conditions of the skin (e.g. urticaria) and the upper and lower airway passages including the nasal and non-nasal symptoms of seasonal allergic rhinitis including nasal congestion in patients in need of such treating.
  • allergic and/or inflammatory conditions of the skin e.g. urticaria
  • the upper and lower airway passages including the nasal and non-nasal symptoms of seasonal allergic rhinitis including nasal congestion in patients in need of such treating.
  • compositions of the present invention were found to be unstable and to discolor when stored in combination with various excipients such as those disclosed in U.S. Patent No. 5,314,697 as part of the matrix core containing pseudoephedrine sulfate.
  • excipients causing discoloration and instability of desloratadine include acidic excipients having a pH of less than 7 in water such as organic acids, such as stearic acid, povidone, crospovidone and carbonyl-containing materials such as lactose, and ethyl cellulose and hydroxylpropyl methylcellulose. Binders like povidone and polymers such as hydroxypropymethylcellulose are useful as a polymer matrix for the sustained release of the pseudoephedrine sulfate from the inner polymer matrix core.
  • the desloratadine could safely be coated onto the first coating.
  • a nasal decongestant e.g..pseudoephedrine sulfate and hydroxypropyl methylcellulose, ethyl cellulose and povidone
  • a first coating comprising a water-swellable film-forming neutral or cationic copolymeric ester, a film modifier and lubricant
  • the desloratadine was found to have an acceptable immediate release profile from the second coating (80% release in 0.1 N HCI in less than about 45 min.) and contain less than about 2% of N-formyldesloratadine, preferably aboutr 1.4% to about 1.6 % of N-formyldesloratadine even after storage for at least 24 months - preferably up to 36 months at 25° C and about 60% relative humidity ("RH").
  • allergic and inflammatory conditions of the skin and airway passages are meant those allergic and inflammatory conditions and symptoms found on the skin and in the upper and lower airway passages from the nose to the lungs.
  • Typical allergic and inflammatory conditions of the skin and upper and lower airway passages include seasonal and perennial allergic rhinitis, non-allergic rhinitis, asthma including allergic and non-allergic asthma, sinusitis, colds (in combination with a NSAID, e.g., aspirin, ibuprofen or acetaminophen) and/or a decongestant e.g. pseudoephedrine), dermatitis, especially allergic and atopic dermatitis, and urticaria and symptomatic dermographism as well as retinophathy, and small vessel diseases, associated with diabetes mellitus.
  • NSAID e.g., aspirin, ibuprofen or acetaminophen
  • decongestant e.g. pseudoe
  • the amount of desloratadine effective for treating or preventing allergic and inflammatory conditions of the skin and upper and lower airway passages will vary with the age, sex, body weight and severity of the allergic and inflammatory condition of the patient.
  • the amount of desloratadine effective for treating or preventing such allergic and inflammatory conditions is in the range of about 2.5 mg/day to about 60 mg/day, preferably about 2.5 mg/day to about 20 mg/day, or about 4.0 mg/day to about 15 mg/day, or about 5.0 mg/day to about 10 mg/day, more preferably about 5.0 mg/day to about 10.0 mg/day, and most preferably about 5.0 mg/day to about 6.0mg/day in a single dose.
  • Desloratadine is a non-sedating long acting histamine antagonist with potent selective peripheral H1 -receptor antagonist activity. Following oral administration, loratadine is rapidly metabolized to descarboethoxyloratadie or desloratadine, a pharmacologically active metabolite. In vitro and in vivo animal pharmacology studies have been conducted to assess various pharmacodynamic effects of desloratadine and loratadine. In assessing antihistamine activity in mice (comparison of
  • desloratadine was relatively free of producing alterations in behavior alterations in behavior, neurologic or autonomic function.
  • the potential for desloratadine or loratadine to occupy brain H1 -receptors was assessed in guinea pigs following i.p. administration and results suggest poor access to central histamine receptors for desloratadine or loratadine.
  • desloratadine has demonstrated anti-allergic and anti-inflammatory activity from numerous in vitro and in vivo tests. These in vitro tests (mainly conducted on cells of human origin) have shown that desloratadine can inhibit many events in the cascade of allergic inflammation.
  • the release of inflammatory cytokines including IL-4, IL-6, IL-8 and IL-13;
  • the release of the inflammatory chemokines such as
  • RANTES regulated upon activation, normal T cell expressed and presumably secreted
  • Superoxide anion production of polymorphonuclear neutrophils The expression of cell adhesion molecules such as intracellular adhesion molecules (ICAM-1 ) and P- selection in endothelial cells; and Eosinophil migration and adhesion
  • the nasal decongestants useful in the present invention include phenylpropanolamine, phenylephnne and and pseudoephedrine.
  • Pseudoephedrine as well as pharmaceutically acceptable acid additional salts, e.g., those of HCI or H 2 SO 4 ⁇ is a sympathomimetic drug recognized by those skilled in the art as a safe therapeutic agent effective for treating nasal congestion and is commonly administered orally and concomitantly with an antihistamine for treatment of nasal congestion associated with allergic rhinitis.
  • the use of pseudoephedrine as a nasal decongestant in the present invention is preferred; the use of pseudoephedrine sulfate is more preferred.
  • the selection of the polymers for the polymer matrix core was critical to achieve the desired extended release period of at least 12 hours, preferably 12 to 16 hours and more preferably for at least 16 hours for pseudoephedrine sulfate.
  • the use of hydroxypropyl methyl cellulose 4,000 cps or 15,000 cps as polymers in the matrix core did not provide this more preferred extended release period of at least 16 hours for dose of pseudoephedrine sulfate.
  • the tablet hardness 22 ⁇ 6 Strong-Cobb Units (SCU) is not greatly affected by the higher level of lubricant (6mg/ tablet) but it is preferred to maintain the lubricant level at I/I0 part by weight of lubricant to one part by weight of povidone as secondary binder.
  • lubricant refers to a substance added to the dosage form to enable the dosage form, e.g., a tablet, after it has been compressed to releases from the mold or die.
  • Suitable lubricants include talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils and the like.
  • magnesium stearate or talc is used.
  • glidants refers to a substance, such as an anti- caking agent, which improves the flow characteristics of a powder mixture.
  • Suitable glidants include silicon dioxide and talc. Preferably, silicon dioxide is used.
  • binder means any material that is added to pharmaceutical compositions to help hold such compositions together and release the medicament therefrom.
  • Suitable binders are selected from the group consisting of: croscarmellose sodium, a cross-linked polymer of carboxymethylcellulose sodium, povidone, crospovidone, starches, celluloses, alginates, and gums; see also USP XXII page 1858 (1990).
  • povidone is used.
  • suitable antifoaming agents include mixtures of homologous liquid methylsiloxane and silica gel available under the Simethecone tradename.
  • water-swellable film-forming neutral or cationic copolymehc ester means neutral and cationic copolymers of ethyl acrylate and substituted unsubstituted methyl or ethyl methacrylate esters.
  • suitable water swellable film-forming neutral copolymehc esters include neutral copolymers of ethyl acrylate and methyl metharylate such as are available from Pharma Poloymers, a company of the H ⁇ ls Group under the EUDRAGIT® Tradename; EUDRAGIT NE30D.
  • aqueous dispersion containing 30% by weight of a neutral copolymer based on ethyl crylate and methyl methoacrylate (average molecular weight of approximately 800,000) is preferred.
  • suitable water-swellable film-forming cationic co-polymeric esters include cationic co-polymerers based on dimethylaminoethylmethacrylate and a neutral methacrylic ester such as the EUDRAGIT E copolymers available from Pharma Polymers as a 12.5% solution (EUDRAGIT E 12.5) or as solid (EUDRAGIT E 100) and quatemay ammonium copolymers described in USP/NF as "Amononio methacrylate copolymer, Type A" and Type "B".
  • EUDRAGIT E copolymers available from Pharma Polymers as a 12.5% solution (EUDRAGIT E 12.5) or as solid (EUDRAGIT E 100)
  • Such copolymers are available as aqueous dispersions of copolymers of acrylic and methacrylic acid esters with a low (substitution) content of quaternary ammonium groups present as salts, (e.g., quaternary ammonium chlorides).
  • Type A and Type B are available as 30% aqueous dispersions under the EUDRAGIT RL 30D and EUDRAGIT RS 30D tradenames, respectively.
  • Use of the water-swellable film-from neutral co-polymeric esters based on ethyl acrylate and methacrylate is preferred.
  • water soluble film modifier as used herein means a film-forming agent which modifies the water-swellable characteristics of the film-forming neutral or cationic copolymehc esters useful in the compositions of the present invention.
  • a typically suitable water soluble film-modifying agent is a low viscosity ( ⁇ 20 cps) cellulose such as low viscosity hydroxypropyl methyl cellulose, low viscosity hydroxylethyl methyl cellulose; low viscosity sodium carboxymethyl cellulose or a ' polyethylene glycol selected from polyethylene glycol 200 to polyethylene glycol 8000.
  • polyethylene glycol 6000 to polyethylene glycol 8000 as a film modifier is preferred in the first and second coatings; the use of polyethylene glycol 8000 in each coating is more preferred.
  • polyethylene glycol in combination with a low viscosity hydroxypropyl methylcellulose in the third coating is preferred.
  • Use of a mixture of polyethylene glycol 8000 and hydroxypropyl methylcellulose 2910 cps in the third or outermost fim coating is more preferred.
  • water insoluble basic calcium, magnesium and aluminium salts means the pharmaceutically acceptable carbonates, phosphates, silicates and sulfates of calcium, magnesium and aluminum or mixtures thereof.
  • suitable pharmaceutically acceptable basic salts include calcium sulfate anhydrous, hydrates of calcium sulfate, such as calcium sulfate dihydrate, magnesium sulfate anhydrous, hydrates of magnesium sulfate, dibasic calcium phosphate, dibasic calcium silicate, magnesium t silicate, magnesium phosphate, aluminum silicate, and hydrates of magnesium phosphate, aluminum phosphate; and calcium phosphate is more preferred.
  • the use of dibasic calcium phosphate dihydrate is most preferred.
  • the hydroxylpropyl methylcellulose 2910 acts as a film-forming agent in the film coating, and the polyethylene glycols act as film modifier.
  • suitable film-forming polymers include low viscosity (720 cps) hydroxypropyl celluloses, methyl hydroxyethyl cellulose and sodium carboxymethyl cellulose.
  • the oral dosage composition of this invention also provides a shelf life of more than 24 months, e.g., up to 36 and 48 months so long as the tablets are stored in standard package at between 2° and 30° C in an ambient environment of 60% relative humidity.
  • the povidone is dissolved in a mixture of alcohol and water.
  • the pseudoephedrine sulfate, hydroxypropyl methylcellulose 2208 USP, 100,000 cps, ethylcelluiose, and dibasic calcium phosphate are blended and granulated with an alcoholic water solution containing povidone.
  • the granulation is milled, and dried to a loss on drying between 0.5 to 2.0%.
  • the dried granulation is milled and blended with requisite amounts of silicon dioxide and magnesium stearate.
  • the final blend is compressed to produce the inner polymer matrix core composition.
  • the coatings are normally applied to the inner polymer matrix cores in the following manner: Cores are charged into a suitable coating pan. A water dispersion of talc, Simethicone, polyethylene glycol 8000 and EUDRAGIT NE30D is applied to the matrix cores as a first coating. These coated matrix cores are then coated with a dispersion of desloratadine, Simethicone, EUDRAGIT NE 30D, polyethylene glycol 8000 NF and talc dispersion. This is followed by an application of third coating containing a dispersion of FD & C Blue No.
  • the geometric mean maximum plasma concentration of pseudoephedrine is about 345 ng/mL to about 365 ng/mL at a time (Tmax) of about 7.60 hours to about 8.40 hours;
  • the geometric mean maximum plasma concentrate of desloratadine (DL) is about 2.10 ng/mL to about 2.45 ng/mL , preferably 2.15 ng/mL to about 2.35 ng/mL at a time (Tmax), of about 4.0 hours to about 4.5 hours
  • the geometric mean maximum plasma concentrate of 3- hydroxydesloratadine (3-OH-DL) is about 0.75 ng/mL to about 1.15 ng/mL, preferably about 0.85 ng/mL to about 1.05 ng/mL , and more preferably preferably about 0.88 ng/mL to about 1.02 ng/mL at a time (Tmax) of about
  • Pharmacokinetic Study No. 1 The pharmacokinetic objective of this study was to determine the bioavailability and bioequivalence of desloratadine (DL), 3-OH DL and pseudoephedrine(PES) from the formulation of Example 2 (5 mg of DL/240 mg of PES) of this application relative to that of a 5 mg of Example 11 of USP No..6, 100, 274 (USP '274) and an extended-release pseudoephedrine core as references.
  • This study was a Phase I, open-label, single-dose, randomized, three-way crossover study with a seven-day washout period between each treatment. Thirty-six healthy male and female subjects received each of the following treatments in the order assigned by a computer-generated random code:
  • Treatment A One 5 mg DL/240 mg PES tablet of Example 2.
  • Treatment B One DL 5 mg tablet of Example 1 1 of USP.'274.
  • Treatment C One 240 mg pseudoephedrine sulphate (oval extended-release pseudoephedrine cores from
  • the tablets were administered with 180 i ⁇ iL (6 fluid ounces) of non- carbonated room temperature water.
  • the tablet was swallowed whole, not chewed or crushed. After dosing, the oral cavity was inspected to assure that the subject had swallowed the tablet.
  • Subjects continued fasting until the four- hour study procedures were complete. Water was permitted throughout the fasting period, except for two hours post-dose. The subjects remained awake and seated upright ambulatory for four hours post-dose. All subjects were confined to the study site until the 120-hour blood samples, vital signs and laboratory tests were obtained.
  • Serial blood samples (10 mL) were to be collected into tubes containing heparin as an anticoagulant at the following time points: 0 (pre-dose), 0.5, 1 , 1.5, 2, 3, 4, 5, 6,8, 10, 12, 16, 20, 24, 36, 48, 48, 72, 96 and 120 hours post- dose. No food was allowed for four hours after dosing. Drinking water was not allowed from one hour pre-dose to one hour postdose, except for the 120 mL administered with the treatment.
  • Plasma concentrations of pseudoephedrine were determined using a validated liquid chromatography with tandem mass spectrometric (LC/MS/MS) method with a lower limit of quantitation (LOQ) of 10.0 ng/mL, and a linear range of 10.0-400 ng/mL
  • LOQ lower limit of quantitation
  • the mean DL Cmax following administration of DL tablet of Example 2 of the present invention or a 5 mg desloratadine tablet of Example 11 of USP 6,100,274 were 1.79 and 2.23 ng/mL, respectively, and were reached at mean Tmax values of 6.78 and 5.10 hours, respectively.
  • the mean 3-OH DL Cmax following administration of 5 mgDL/240 mgPES tablet of Example 2 of this application and a 5 mg desloratadine tablet of Example 11 of USP 6,100,274 were 0.695 and 0.832 ng/mL, respectively, and were reached at mean Tmax values of 6.09 and 4.96 hours, respectively.
  • the peak plasma concentration of 3-OH DL decreased slowly with half-life of 29.6 hours following administration of 5 mgDL/240 mgPES tablet of Example 2 of this application, and 29.5 hours following administration of the 5 mg DL tablet of USP 6,100,274.
  • a %C V is percent coefficient of variation, which is a relative measure of variability. See Steele and Tor ⁇ e, "Principles and Procedures of Statistics", (1980) 2 nd Edition, McGraw-Hill, NY, at page 27.
  • Example 2 /240 mgPES tablet of Example 2 or a 240 mg pseudoephedrine sulphate extended- release core were 328 and 349 ng/mL, respectively.
  • the power to detect a 20% difference in treatment means at an ⁇ -level of 0.05 (two-tailed) for the log- transformed Cmax and AUC(tf) were 100 and 93%, respectively.
  • the 90% confidence intervals for pseudoephedrine met the 80-125% bioequivalence guidelines for both Cmax and AUC(tf). For those subjects were AUC(I) could be determined, the confidence intervals for AUC(I) also met the 80-125 guidelines.
  • Subjects were confined at the study site at least 12 hours prior to each treatment (Day - 1 ). In the morning of Day 1 , following a ten-hour overnight fast, each subject received one of the following treatments based on his/her subject number and the study period:
  • Treatment A One (5 mg DL/240 mgPES) tablet of Example 2 of this application
  • Treatment B One (6 mgDL/240 mgPES) tablet of Example 3 of this application
  • Treatment C One 5 mg DL tablet of Example 11 of USP'274 plus one 120mg PES tablet (oval extended-release pseudoephedrine core)
  • the mean pharmacokiinetic parameters are shown in Table 3.
  • the power to detect a 20% difference in treatment means of DL at an ⁇ -leval of 0.05 (two tailed) for the log-transformed AUC(tf), AUC(I), and Cmax values were 89%, 90% and 88% respectively.
  • 1 %CV is percent coefficient of variation, which is a relative measure of variability
  • Treatment B One (6 mg/240 mg) tablet of Example 3
  • Treatment C One 5 mg DL tablet of Example II of USP 6,100,274 plus one 240 mg pseudoephedrine tablet
  • Example 2 is not equivalent to the 5 mg DL tablet of Example 1 1 of USP '274 and that the 6 mgDL/240 PESmg of Example 3 and 5 mg DL tablet of Example II of USP ',274 are bioequivalent.
  • Treatment B DL 5 mg of Examplel 1 of USP '274
  • ⁇ .%CV is percent coefficient of variation, which is a relative measure of variability
  • step 1 Disperse Simethicone and polyethylene glycol 8000 in a portion of purified water and agitate until completely dissolved.
  • step 2 To the product of step 1 , add the remainder of the purified water and the talc; stir the so-formed suspension at room temperature until homogeneous.
  • step 2 Slowly add the so-formed homogeneous suspension of step 2 to the stirred EUDRAGIT NE30D dispersion and continue to mix the so-formed mixture until a homogeneous dispersion is formed. Pass the dispersion through a screen.
  • step 2 Slowly add desloratadine to the dispersion of step 1 and mix until a uniform dispersion is formed. Combine with the talc with the so-formed uniform dispersion, and continue agitation until a homogenous suspension is formed. (3) Add dispersion of step 2 to the EUDRAGIT NE 30D dispersion and mix until a uniform dispersion is formed. Pass the dispersion through a screen.
  • step 1 Add the solution of step 1 to the dispersion of step 3 and continue to mix until
  • step 6 Slowly add the mixture of step 6 to a dispersion of EUDRAGIT NE30D and continue to mix until homogeneous. (8) Pass dispersion of step 6 through 60 mesh screen.
  • Example 3 The in vitro dissolution profile of the tablet of Example 1 was measured in a stirred 0.1 N HCI solution at 37°C (1 st hour) and thereafter in a stirred phosphate buffer having a pH of 7.5 at 37°C. The 80% of desloratadine in the coating was dissolved within the first 45 minutes and the total dose of pseudoephedrine sulfate in the matrix core was slowly released via erosion and dissolution mechanisms over a period of at least 16 hours.
  • Example 3 The in vitro dissolution profile of the tablet of Example 1 was measured in a stirred 0.1 N HCI solution at 37°C (1 st hour) and thereafter in a stirred phosphate buffer having a pH of 7.5 at 37°C. The 80% of desloratadine in the coating was dissolved within the first 45 minutes and the total dose of pseudoephedrine sulfate in the matrix core was slowly released via erosion and dissolution mechanisms over a period of at least 16 hours.
  • Example 3
  • Example 4 The following more preferred composition of the present invention was made in accordance with the above procedure of Example 1. 1. Matrix Core
  • Matrix Core Weight 800mg Matrix Core Coatings 5.
  • pseudoephedrine hydrogen chloride was used in place of pseudoephedrine sulfate.
  • compositions of the present invention are useful for treatment of allergic and/or inflammatory conditions of the skin (e.g. urticaria) and the upper and lower airway passages including the nasal and non-nasal symptoms of seasonal allergic rhinitis including nasal congestion in patients in need of such treating.
  • the precise dosage and dosage regimen may be varied by the attending clinician in view of the teachings herein depending upon the requirements of the patient, e.g., the patient's age, sex and the severity of the allergic and/or inflammatory condition being treated. Determination of the proper dosage and dosage regimen for a particular patient will be within the skill of the attending clinician.

Abstract

L'invention concerne une composition de dose orale solide à libération prolongée enrobée, contenant un décongestionnant nasal, de la pseudoéphédrine ou un sel de celle-ci, par exemple, de la pseudoéphédrine sulfate dans un noyau permettant de fournir une concentration plasmique géométrique maximale de pseudoéphédrine d'environ 345 ng/mL à environ 365 ng/mL pendant une durée comprise entre environ 7 h 60 et environ 8 h 40 et présentant deux ou trois enrobages entourant le noyau, le deuxième enrobage contenant une quantité d'antihistaminique non sédatif, la desloratadine, permettant de fournir une concentration plasmique géométrique maximum de desloratadine d'environ 2,15 ng/mL à environ 2,45 ng/mL pendant une durée comprise entre 4 h et environ 4 h 30. L'invention concerne également l'utilisation de cette composition pour le traitement de patients présentant des signes et des symptômes associés aux affections allergique et/ou inflammatoires de la peau et des voies respiratoires.
PCT/US2000/034412 1999-12-20 2000-12-19 Composition de dose orale a liberation prolongee WO2001045668A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU22771/01A AU2277101A (en) 1999-12-20 2000-12-19 Stable extended release oral dosage composition
US10/175,460 US6979463B2 (en) 1999-12-20 2002-06-19 Stable extended release oral dosage composition
US11/244,743 US7820199B2 (en) 1999-12-20 2005-10-06 Stable extended release oral dosage composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17283699P 1999-12-20 1999-12-20
US60/172,836 1999-12-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/175,460 Continuation-In-Part US6979463B2 (en) 1999-12-20 2002-06-19 Stable extended release oral dosage composition

Publications (2)

Publication Number Publication Date
WO2001045668A2 true WO2001045668A2 (fr) 2001-06-28
WO2001045668A3 WO2001045668A3 (fr) 2001-12-13

Family

ID=22629437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034412 WO2001045668A2 (fr) 1999-12-20 2000-12-19 Composition de dose orale a liberation prolongee

Country Status (38)

Country Link
US (2) US6979463B2 (fr)
EP (2) EP2196195A3 (fr)
JP (3) JP5042403B2 (fr)
KR (2) KR100936572B1 (fr)
CN (3) CN1211079C (fr)
AR (1) AR027033A1 (fr)
AT (1) ATE463240T1 (fr)
AU (4) AU2277101A (fr)
BR (1) BR0006403A (fr)
CA (1) CA2329217C (fr)
CO (1) CO5251435A1 (fr)
CY (1) CY1110693T1 (fr)
CZ (1) CZ302860B6 (fr)
DE (1) DE60044117D1 (fr)
DK (1) DK1112738T3 (fr)
EC (1) ECSP003836A (fr)
EG (1) EG23759A (fr)
ES (1) ES2341751T3 (fr)
HK (1) HK1034453A1 (fr)
HU (1) HUP0004988A3 (fr)
ID (1) ID28675A (fr)
IL (1) IL140450A (fr)
MX (1) MXPA00013037A (fr)
MY (1) MY130773A (fr)
NO (1) NO331645B1 (fr)
NZ (1) NZ509028A (fr)
PE (1) PE20010982A1 (fr)
PL (1) PL211573B1 (fr)
PT (1) PT1112738E (fr)
RU (2) RU2303440C2 (fr)
SA (2) SA06270069B1 (fr)
SG (1) SG109438A1 (fr)
SI (1) SI1112738T1 (fr)
SK (1) SK287684B6 (fr)
TR (1) TR200003787A2 (fr)
TW (1) TWI225414B (fr)
WO (1) WO2001045668A2 (fr)
ZA (1) ZA200007715B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000264A1 (fr) * 2001-06-20 2003-01-03 Schering Corporation Antihistaminiques pour le traitement de congestion nasale et d'obstruction nasale
US7902208B2 (en) 2000-02-03 2011-03-08 Schering Corporation Treating allergic and inflammatory conditions
US8834923B2 (en) 2005-12-01 2014-09-16 Pierre Fabre Medicament Slow-release composition, method for the preparation thereof, and use thereof
WO2022023463A1 (fr) 2020-07-30 2022-02-03 Faes Farma, S.A. Système d'administration de médicaments décongestionnants

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287684B6 (sk) 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
CA2476201C (fr) 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Formulations a liberation modifiee d'au moins une forme de tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US20040229896A1 (en) * 2003-03-12 2004-11-18 Toth Zoltan G. Stable pharmaceutical compositions of desloratadine
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US20070116764A1 (en) * 2003-12-01 2007-05-24 Shigeyuki Marunaka Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing
JP2008517938A (ja) * 2004-10-25 2008-05-29 シェーリング コーポレイション 呼吸器障害を処置するために他の活性剤と組み合わせたｍ１レセプターアンタゴニストおよび／またはｍ３レセプターアンタゴニスト
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20070014855A1 (en) * 2005-07-12 2007-01-18 Rahul Gawande S Stable desloratadine compositions
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
NZ573174A (en) * 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
SG172664A1 (en) * 2006-06-01 2011-07-28 Schering Plough Healthcare Phenylephrine pharmaceutical formulations and compositions for colonic absorption
CN101472561A (zh) * 2006-06-01 2009-07-01 先灵公司 去氧肾上腺素脉冲释放制剂和药物组合物
AU2007254826B2 (en) * 2006-06-01 2013-10-24 Merck Sharp & Dohme Corp. Pharmaceutical compositions for sustained release of phenyephrine
MX2009000320A (es) * 2006-07-11 2009-06-05 Mutual Pharmaceutical Co Formulaciones de liberacion controlada.
CN101848706A (zh) * 2007-06-01 2010-09-29 先灵-普劳健康护理产品公司 包含底物和含活性成分和聚乙烯醇的包衣的药用组合物
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
EP3045043B1 (fr) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
WO2010143202A1 (fr) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique
TR201009396A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
DE102016107760B4 (de) 2016-04-26 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Essbare Funktionsschichten und Überzüge auf Hybridpolymerbasis für Pharmazie und Lebensmittel
US20180187263A1 (en) 2017-01-05 2018-07-05 Iowa State University Research Foundation, Inc. Kits for diagnostic detection and prevention of feedlot bovine respiratory disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100675A (en) * 1989-05-03 1992-03-31 Schering Corporation Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100000A (en) 1870-02-22 Improved sun-bonnet for horses
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3940485A (en) 1973-12-12 1976-02-24 Levinson Harold N Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
US4008796A (en) 1974-03-26 1977-02-22 General Concrete Of Canada Limited Control method for feeding items on a conveyor
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
HU194864B (en) 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) 1984-04-09 1988-11-08 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
SE8404467D0 (sv) 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4804666A (en) 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
JPS6396126A (ja) 1986-10-13 1988-04-27 Taisho Pharmaceut Co Ltd 安定化組成物
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4777170A (en) 1987-02-03 1988-10-11 Heinrich William A Method to prevent and treat the signs and symptoms of motion sickness
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5019591A (en) 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
ZA914764B (en) 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
MX9202350A (es) 1991-05-20 1992-11-01 Alza Corp Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
JP2646972B2 (ja) 1993-11-01 1997-08-27 日本電気株式会社 多ビットメモリ
DE4442999A1 (de) 1994-12-02 1996-06-05 Hexal Pharma Gmbh Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP2000505104A (ja) * 1996-10-31 2000-04-25 シェーリング コーポレイション 喘息の治療のためのロラタジンおよび充血除去剤を含む組成物
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5900421A (en) 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6506767B1 (en) 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
CA2307790A1 (fr) 1997-10-29 1999-05-06 J-Med Pharmaceuticals, Inc. Schema posologique de traitement de la rhinite a base d'antihistaminique et de decongestionnant
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
AU741201B2 (en) 1998-07-10 2001-11-22 Merck Sharp & Dohme Corp. 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6) cyclohepta (1,2-b)pyridine oral compositions
US6423721B1 (en) 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6051585A (en) 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6100274A (en) 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
SK287684B6 (sk) 1999-12-20 2011-06-06 Schering Corporation Pevná orálna farmaceutická dávková forma s predĺženým uvoľňovaním
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001056571A1 (fr) 2000-02-03 2001-08-09 Schering Corporation Traitement d'etats allergiques et inflammatoires
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
KR20020093982A (ko) 2000-05-19 2002-12-16 알콘, 인코퍼레이티드 알레르기성 질환 치료를 위한 아닐린 디설파이드 유도체
US6599913B1 (en) 2001-06-29 2003-07-29 Schering Corporation Treating allergic and inflammatory conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100675A (en) * 1989-05-03 1992-03-31 Schering Corporation Sustained release tablet comprising loratadine, ibuprofen and pseudoephedrine
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARDELUS IGNASI ET AL: "Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 374, no. 2, 18 June 1999 (1999-06-18), pages 249-254, XP002166884 ISSN: 0014-2999 *
KOSOGLOU T; RADWANSKI E; BATRA V.K.: "Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once-versus twice-daily combination tablet formulations in healthy adult males" CLINICAL THERAPEUTICS, vol. 19, no. 5, 1997, pages 1002-1012, XP000926408 *
KREUTNER WILLIAM ET AL: "Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: 2nd communication: Lack of central nervous system and cardiovascular effects." ARZNEIMITTEL-FORSCHUNG, vol. 50, no. 5, 2000, pages 441-448, XP002166885 ISSN: 0004-4172 *
NOMEIR A.; MOJAVERIAN P; KOSOGLOU T.: "Influence of food on the oral bioavailabilty of loratadine and pseudophedrine from extended-release tablets in healthy volunteers" JOURNAL OF CLINICAL PHARMACOLOGY, vol. 36, 1996, pages 923-930, XP000926410 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902208B2 (en) 2000-02-03 2011-03-08 Schering Corporation Treating allergic and inflammatory conditions
WO2003000264A1 (fr) * 2001-06-20 2003-01-03 Schering Corporation Antihistaminiques pour le traitement de congestion nasale et d'obstruction nasale
US8834923B2 (en) 2005-12-01 2014-09-16 Pierre Fabre Medicament Slow-release composition, method for the preparation thereof, and use thereof
WO2022023463A1 (fr) 2020-07-30 2022-02-03 Faes Farma, S.A. Système d'administration de médicaments décongestionnants

Also Published As

Publication number Publication date
ECSP003836A (es) 2002-02-25
EP1112738A3 (fr) 2001-07-18
PL344715A1 (en) 2001-07-02
US7820199B2 (en) 2010-10-26
CN101081224B (zh) 2012-05-30
CZ20004812A3 (cs) 2001-08-15
EP1112738B1 (fr) 2010-04-07
EP1112738A2 (fr) 2001-07-04
EP2196195A3 (fr) 2012-02-29
SA01210741A (ar) 2005-12-03
NO20006504D0 (no) 2000-12-20
KR20110028326A (ko) 2011-03-17
NZ509028A (en) 2002-12-20
CN1301534A (zh) 2001-07-04
HK1034453A1 (en) 2001-10-26
EP2196195A2 (fr) 2010-06-16
ID28675A (id) 2001-06-21
CN1679569A (zh) 2005-10-12
US20060159761A1 (en) 2006-07-20
IL140450A (en) 2011-11-30
RU2007104095A (ru) 2008-08-10
TWI225414B (en) 2004-12-21
SK19672000A3 (sk) 2001-09-11
PE20010982A1 (es) 2001-09-28
RU2423106C9 (ru) 2012-06-27
AU2009200460A1 (en) 2009-02-26
KR20010062542A (ko) 2001-07-07
AU2005203771A1 (en) 2005-09-15
CN101081224A (zh) 2007-12-05
BR0006403A (pt) 2001-07-17
RU2303440C2 (ru) 2007-07-27
ZA200007715B (en) 2001-06-20
KR100936572B1 (ko) 2010-01-13
CY1110693T1 (el) 2015-06-10
WO2001045668A3 (fr) 2001-12-13
DE60044117D1 (de) 2010-05-20
AU2009200460B2 (en) 2012-01-19
PL211573B1 (pl) 2012-05-31
HUP0004988A2 (hu) 2002-11-28
ATE463240T1 (de) 2010-04-15
IL140450A0 (en) 2002-02-10
CO5251435A1 (es) 2003-02-28
CZ302860B6 (cs) 2011-12-21
PT1112738E (pt) 2010-06-04
JP2012224642A (ja) 2012-11-15
JP5042403B2 (ja) 2012-10-03
JP2001172174A (ja) 2001-06-26
AU7244300A (en) 2001-06-21
RU2423106C2 (ru) 2011-07-10
SK287684B6 (sk) 2011-06-06
SA01210741B1 (ar) 2006-10-31
HU0004988D0 (fr) 2001-02-28
CN1211079C (zh) 2005-07-20
DK1112738T3 (da) 2010-06-28
SI1112738T1 (sl) 2010-07-30
US20030086971A1 (en) 2003-05-08
US6979463B2 (en) 2005-12-27
ES2341751T3 (es) 2010-06-28
SA06270069B1 (ar) 2009-06-07
MXPA00013037A (es) 2003-06-19
TR200003787A3 (tr) 2001-07-23
AU781924B2 (en) 2005-06-23
KR101234940B1 (ko) 2013-02-19
EG23759A (en) 2007-08-08
HUP0004988A3 (en) 2008-04-28
MY130773A (en) 2007-07-31
JP2008081510A (ja) 2008-04-10
NO20006504L (no) 2001-06-21
NO331645B1 (no) 2012-02-13
CA2329217A1 (fr) 2001-06-20
TR200003787A2 (tr) 2001-07-23
CA2329217C (fr) 2006-10-31
SG109438A1 (en) 2005-03-30
AU2277101A (en) 2001-07-03
AR027033A1 (es) 2003-03-12

Similar Documents

Publication Publication Date Title
US7820199B2 (en) Stable extended release oral dosage composition
US8187630B2 (en) Extended release oral dosage composition
CA2147606C (fr) Composition stable pour administration par voie orale, a liberation prolongee
KR101199654B1 (ko) 안정한 서방출형의 경구 투여용 조성물

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP